Company Overview - Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, specifically addressing drug resistance and central nervous system involvement [3][6] - The company operates a biotechnology business model, emphasizing research and development of novel small molecule inhibitors for oncology [1][11] Product Pipeline - Nuvalent's lead candidates include NVL-520, a ROS1-selective inhibitor, and NVL-655, an ALK-selective inhibitor, both aimed at overcoming resistance and treating brain metastases in cancer patients [2][3] Recent Financial Activity - As of November 14, 2025, Nuvalent shares were priced at $96.50, reflecting a 7.0% increase over the past year, although the shares underperformed the S&P 500 by 5.7 percentage points [4] - Bain Capital Life Sciences Investors, LLC, fully divested its stake in Nuvalent, selling 1,447,267 shares valued at approximately $110.43 million, marking a significant portfolio shift as this position previously constituted 13.8% of the fund's assets under management [5][6] Market Context - The biotech sector, which includes companies like Nuvalent, presents challenges for average investors due to complexities in drug pipelines, pricing power, and clinical trial statuses [6][8] - Biotech-focused exchange-traded funds (ETFs), such as the State Street SPDR S&P Biotech ETF (XBI), may offer a more diversified investment approach within the sector, having generated a total return of 25% over the last year, outperforming the S&P 500's 14% return [7][8]